<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04552964</url>
  </required_header>
  <id_info>
    <org_study_id>CONDORE</org_study_id>
    <nct_id>NCT04552964</nct_id>
  </id_info>
  <brief_title>Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma</brief_title>
  <acronym>CONDORE</acronym>
  <official_title>Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Thea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires Thea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glaucoma is one of the most common chronic pathologies and affects several millions patients.&#xD;
      Among these, many have a poorly controlled glaucoma, damaging vision and leading to&#xD;
      blindness.&#xD;
&#xD;
      One between principal reasons for poor glaucoma medication adherence is forgetfulness. To&#xD;
      improve this issue, digital tools may benefit both ophthalmologists and patients by&#xD;
      monitoring eye drop administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 25, 2020</start_date>
  <completion_date type="Actual">April 27, 2021</completion_date>
  <primary_completion_date type="Actual">April 27, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This will be a single centre, single-arm, prospective pilot study.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global patient satisfaction</measure>
    <time_frame>Week 9</time_frame>
    <description>Global patient satisfaction (Patient satisfaction questionnaire)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This will be a single centre, single-arm, prospective pilot study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Single arm</intervention_name>
    <description>Far Best Corrected Visual Acuity (BCVA) ; Intra-Ocular Pressure (IOP) assessment ; Fundus examination ; Automated visual field ; Slit lamp examination ; Pregnancy test ; Patient Satisfaction Questionnaire</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient &gt; 18 years old, both genders&#xD;
&#xD;
          2. Diagnosed with glaucoma, with controlled IOP (&lt;18mmHg)&#xD;
&#xD;
          3. Currently receiving a topical glaucoma treatment&#xD;
&#xD;
          4. Receiving a multitherapy a fixed combination of dorzolamide-timolol,&#xD;
             preservative-free.&#xD;
&#xD;
          5. Patient willing to participate in the study.&#xD;
&#xD;
          6. Patient familiar with a smartphone and its applications&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with any eye condition in addition to glaucoma requiring expected additional&#xD;
             treatment&#xD;
&#xD;
          2. Patient with an ongoing or known history of ocular allergy and/or uveitis and/or viral&#xD;
             infection and or ocular infection.&#xD;
&#xD;
          3. Patient who underwent intraocular surgery within the past 3 months or scheduled to&#xD;
             undergo intraocular surgery within the next 3 months&#xD;
&#xD;
          4. Patient with best-correct visual acuity &lt;20/70 in the better seeing eye&#xD;
&#xD;
          5. Patient whose drop administration is performed by someone else&#xD;
&#xD;
          6. Alcohol addiction and/or heavy smoker, according to the investigator's judgement.&#xD;
&#xD;
          7. Patient inability to understand the study procedures or to give informed consent.&#xD;
&#xD;
          8. Non-compliant patient (e.g., not willing to attend a visit; way of life interfering&#xD;
             with compliance).&#xD;
&#xD;
          9. Participation in this study at the same time as in another clinical study.&#xD;
&#xD;
         10. Patient being institutionalized because of legal or regulatory order, inmate of&#xD;
             psychiatric wards, prison or state institutions, or employee of the study sites or of&#xD;
             the sponsor's company.&#xD;
&#xD;
         11. Patient not covered by the government health care scheme of the country in which&#xD;
             he/she is living (if applicable).&#xD;
&#xD;
         12. Women of childbearing potential, pregnant or breastfeeding: Childbearing potential is&#xD;
             defined as a woman who is not using a reliable method of contraception (oral&#xD;
             contraceptive, intrauterine device, subcutaneous contraceptive implant, vaginal ring,&#xD;
             patch) or is not surgically sterilized.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Baptiste DERIOT, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre d'Ophtalmologie Blatin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuelle ALBERTINI, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre d'Ophtalmologie Blatin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre d'Ophtalmologie Blatin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

